The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

850

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1995

Conditions
Cytomegalovirus RetinitisHIV InfectionsGastrointestinal Diseases
Interventions
DRUG

Ganciclovir

Trial Locations (17)

10011

Clinical Directors Network of Region II, New York

10037

Harlem AIDS Treatment Group / Harlem Hosp Ctr, New York

10456

Bronx Lebanon Hosp Ctr, The Bronx

11201

Addiction Research and Treatment Corp, Brooklyn

19899

Wilmington Hosp / Med Ctr of Delaware, Wilmington

20422

Veterans Administration Med Ctr / Regional AIDS Program, Washington D.C.

23298

Richmond AIDS Consortium, Richmond

30308

AIDS Research Consortium of Atlanta, Atlanta

48201

Comprehensive AIDS Alliance of Detroit, Detroit

48202

Henry Ford Hosp, Detroit

60657

AIDS Research Alliance - Chicago, Chicago

70112

Louisiana Comm AIDS Rsch Prog / Tulane Univ Med, New Orleans

80204

Denver CPCRA / Denver Public Hlth, Denver

94110

Community Consortium of San Francisco, San Francisco

97210

Portland Veterans Adm Med Ctr / Rsch & Education Grp, Portland

07033

Schering - Plough Corp, Kenilworth

07103

North Jersey Community Research Initiative, Newark

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001034 - The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIV | Biotech Hunter | Biotech Hunter